Bone Marrow Transplant Market

Bone Marrow Transplant Market Outlook

The bone marrow transplant market is anticipated to flourish at an average CAGR of 3.4% between 2023 and 2033. The market is expected to hold a market share of USD 14.86 billion by 2033, while the market is likely to reach a value of USD 10.65 billion in 2023. A historical CAGR of 2.5% has been recorded by the experts of Future Market Insights for the market concerned.

The hematopoietic stem cell is a soft vascular tissue in the interiors of long bones, and a bone marrow transplant is identified as the procedure to replace the damaged or destroyed bone marrow with healthy bone marrow stem cells.

Attributes	Details
Bone Marrow Transplant Market CAGR (2023 to 2033)	3.4%
Bone Marrow Transplant Market Size (2023)	USD 10.65 billion
Bone Marrow Transplant Market Size (2033)	USD 14.86 billion

The bone marrow transplant procedure is prescribed for the treatment of advanced stages of leukemia, Hodgkin, and non-Hodgkin lymphomas, multiple myeloma, aplastic and sickle cell anemia, thalassemia, and other diseases. Increasing awareness, combined with an increase in initiatives run by healthcare practitioners, is majorly responsible for the global growth of the market.

Market Scenario Analysis Potential Drivers and Restraints

The market is anticipated to have mixed dynamics contributing to the bearish propulsion of the bone marrow transplant market. Several factors impacting the expansion of the market are identified during the study.

Besides the factors influencing growth, it is also identified that certain aspects can limit growth and curb the pace of growth further in the market.

Drivers:

• The key factor affecting the bone marrow transplant industry is the surge in the prevalence of blood cancer and other blood-related diseases. The statistics predicted by the experts of FMI are anticipated to help the forum propel over the forecast period.
• The growing incidences of non-Hodgkin and Hodgkin lymphoma, thalassemia, and leukemia, along with the common bone marrow diseases around the world, the developments in technology, and the enhancement of the healthcare infrastructure are likely to drive the market in the long run.
• A steep increase in the development of stem cell cryopreservation, identified as the need of the hour, is majorly contributing to the bone marrow transplant market and is likely to gain further traction in the upcoming years.
• An increase in research and development activities is projected to boost the market, and new products are being launched that may help the industry flourish over the forecast period.
• A rise in funding for logistic services and growing per capita healthcare expenses are expected to propel the market's growth.

Restraints:

• It is identified that there is a high expenditure associated with the treatment, and the high cost of bone marrow transplant is likely to serve as a deterring factor for the bone marrow transplant market, as a large section of the populace cannot afford such expensive treatment of the diseases.
• There is a shortage of bone marrow donors, which is an aspect responsible for the impeding growth of the bone marrow transplant market in the near future.
• The lack of reimbursement policies for organ transplantation procedures in emerging economies and developed countries is expected to hamper the growth of the industry during the period.

Country-wise Insights

Country	Revenue Share % (2022)
United States	30.3%
Germany	11.9%
Japan	2/0%
North America	32.3%
Europe	53.1%

Country	CAGR % (2023 to 2033)
China	4.2%
India	3.4%
United Kingdom	2.4%
Australia	3.1%

Overview of the North America Bone Marrow Transplant Market

North America is projected to secure steady bone marrow transplant market growth during the forecast period. The region cumulatively held 32.3% market share of the global bone marrow transplant market in 2022.

The factors attributing to the growth can be mentioned as follows:

• There is a growth in the healthcare infrastructure of North America; capital expenditures are initiated by the key players prevailing in this region, coupled with an installed base for different kinds of products for the bone marrow transplant market.
• It is anticipated that the North American region is having favorable regulatory scenarios that are likely to impact the bone marrow transplant market positively.

European Region Bolstering the Global Bone Marrow Transplant Market

Europe is projected to dominate the global market for bone marrow transplants during the forecast period. At present, Europe holds 53.1% of the total market share for bone marrow transplants worldwide in 2022.

The reasons owing for such extensive market expansion are mentioned below:

• The increasing geriatric population of Europe is widely driving the bone marrow transplant market as they are more prone to severe diseases.
• The innovative healthcare systems have introduced bone marrow transplants in their contributions and the state-of-the-art public facilities, which may further boost the growth of the bone marrow transplant market in the region during the forecast period.
• New technology penetration in Europe is another factor boosting the concerned market of the region.

Categorical Analysis

Category	By Transplant Type
Leading Segment	Autologous
Market Share (2022)	54.5%

Category	By End User
Leading Segment	Hospital
Market Share (2022)	90.3%

Start-up Ecosystem

The start-ups in the bone marrow transplant market are indulging in collaborations and continually making innovations to stem cell transplant procedures to further make it convenient and cost-efficient for the population.

Company Name	Magenta Therapeutics, Cambridge (United States)
Total Funding	USD 151 million
Description	Developed stem cell-based therapies for autoimmune disease, genetic blood disorders, and cancer. The company has developed stem cell transplants by using targeted antibodies, stem cell harvesting using new biologic agents, and increasing stem cell numbers by targeting self-renewal pathways.

Company Name	Kiadis Pharma, Amsterdam (Netherlands)
Total Funding	USD 33 million
Description	Kiadis Pharma is a developer of therapeutic solutions for hematopoietic stem cell transplants. It is focused on developing solutions for complications and limitations of hematopoietic stem cell transplants (HSCT) in blood cancer patients. The company uses all depleted T-cell immunotherapeutics (ATIR) to support the patient’s newly transplanted immune system before it becomes fully functional. This enables better acceptance of even haploidentical (or lower) stem cell donors. Kiadis is investigating the use of ATIR in leukemia and thalassemia.

Company Name	Talaris, Boston
Total Funding	USD 215 million
Description	Talaris Therapeutics is involved in developing single-dose cell therapy to treat living donor kidney transplant tolerance. They have developed a proprietary technology that allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs). The lead candidate, FCR001, is in phase III clinical trial, which is being investigated for living donor kidney transplant tolerance.

Competitive Landscape

The bone marrow transplant market is highly competitive and consists of several leading players. To increase their global market presence, market leaders are engaging in various product launches, mergers and acquisitions, and development activities focusing on orthopedic surgical treatments.

Recent Developments

Some Recent Developments Identified in the Analysis are:

• In May 2020, Gamida Cell Ltd., an advanced cell therapy company committed to finding cures for blood cancer and serious blood diseases, declared positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, investigational advanced cell therapy in development as a potentially life-saving treatment option for patients in need of bone marrow transplant.
• In November 2019, Lonza Group Ltd. partnered with Cryoport, Inc. in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network.
• In September 2017, Inotek Pharmaceuticals entered into a definitive merger agreement with Rocket Pharmaceuticals, a United States-based gene therapy company.

Key Players

• Merck Millipore Corporation
• Sanofi-Aventis LLC.
• AllCells LLC.
• STEMCELL Technologies
• ATCC Inc.
• Hemacare Corporation
• Cellular Dynamics International
• ReachBio LLC.
• Conversant Bio ABM Inc.
• PromoCell GmbH
• Cruline Human biospecimen PRO
• Lifeline Cell Technology
• Mesoblast Ltd.

Key Segments Covered

By Transplant Type:

• Autologous
• Allogeneic

By Disease Indication:

• Leukemia
• Lymphoma
• Myeloma
• Others (anemia, thalassemia, etc.)

By End User:

• Hospitals
• Multispecialty Clinics
• Ambulatory Surgical Centers
• Others

Key Regions Covered:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • United Kingdom
  • France
  • Spain
  • Russia
  • Rest of Europe
• Japan
• Asia Pacific Excluding Japan
  • China
  • India
  • Malaysia
  • Singapore
  • Australia
  • Rest of Asia Pacific Excluding Japan (APEJ)
• The Middle East and Africa
  • GCC Countries
  • Israel
  • South Africa
  • Middle East and Africa (MEA)

Frequently Asked Questions

How Significant Is the Current Market?

The market is anticipated to be valued at USD 10.65 billion in 2023.

How Has the Market Developed in The Past?

The global market advanced at a 2.5% HCAGR from 2018 to 2022.

What Is the Projected Market Growth Between 2023 And 2033?

Up until 2033, the market is anticipated to thrive at a CAGR of 3.4%.

How Much of The Market Is Accounted for By the United States?

Potentially holding 32.3% of the market in North America.

What is The Market Share of Europe?

The market has been dominated by Europe, 53.1%.

What Will the Market Be Worth In 2033?

By 2033, the market is anticipated to be worth USD 14.86 billion.

What Is the Prominent Transplant Type on The Market?

The autologous category to escalate to a market share of 54.5% in 2023.